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Solid organ transplantation (SOT) is currently recognized as the treatment of choice of 
patients with end-stage disease, but the length and type of pharmacologic immunosuppression 
strongly affect patients’ immune system resulting in enhanced immune evasion strategies, 
oncogenic virus reactivation and malignant transformation. On these grounds, a more in depth 
characterization of functional defects of immune cells related to the different 
immunosuppressive regimens and the occurrence of relevant clinical events might be relevant 
to design novel and integrated cancer surveillance practices for immune suppressed transplant 
recipients. The main purpose of this study is to identify a reliable immunologic profile 
predictive of cancer development and progression in SOT patients through a multiparametric 
phenotypic and functional characterization of dendritic cells (DCs) and T lymphocytes in 
SOT patients treated with different immunosuppressive regimens.  In particular, the activation 
status of these cells was assessed in serial samples through Multispectral imaging flow 
cytometry, whereas the extent of T-cell responses specific for pathogenic viruses and tumor-
associated antigens was measured by ELIspot IFN-γ assay. Data obtained in SOT patients 
who developed a tumor (n=15) were compared with those from patients tumor-free during the 
follow-up (n=58). Interestingly, we observed that patients experiencing cancer onset during 




 T lymphocytes and a decreased 
activation of monocyte-derived DCs as compared with the “no tumor” cohort and healthy 
donors. Moreover, we found that tumor onset patients display higher spontaneous T-cells 
responses against the “universal” tumor associated-antigens hTERT and Survivin if compared 
to “no tumor” patients and healthy controls. Globally, patients of the “tumor” cohort showed 
significantly higher levels of circulating hTERT mRNA as compared to those of the “no 
tumor” cohort, even before the diagnosis of cancer, suggesting that this biomarker could 
usefully complement the immunomonitoring of SOT patients and help identify those at risk of 
cancer. We also found that the levels of HPV-specific T-cell responses observed in both 
patient cohorts were significantly lower both at baseline and at follow up as compared to 
those of healthy donors, whereas no difference was detected with regard to T-cell responses 
specific for CMV and EBV. Given the critical role of severe immunosuppression that 
characterizes transplanted patients and the importance of immune surveillance integrity in the 
prevention and control of malignancies, the results of the present study provide a strong 
rationale to design and activate a prospective study in a larger cohort of SOT patients aimed at 
validating the role of the immune biomarkers identified as potential predictors of the risk of 





1.1 Solid organ transplantation and immunosuppressive regimen  
 
1.1.1  Background 
Solid organ transplantation (SOT) is currently recognized as the treatment of choice of 
patients with end-stage disease and the availability of potent anti-rejection drugs significantly 
reduced the occurrence of acute and chronic allograft rejections, even though long-term 
survival is still poor (1). Indeed, tumor onset, viral infections/reactivations and cardiovascular 
complications are among the major causes of morbidity and mortality in solid organ 
transplanted patients (OTRs) (2,3). Therefore, if on one side organ transplantation is the only 
treatment available for some end-stage diseases, on the other side the duration and type of 
immunosuppression can increase the risk of de novo malignancies and impair the control of 
viral infections and reactivation. In this respect, the unavoidable life-long immunosuppression 
plays a critical role in the increased incidence and risk of cancer development in OTRs. These 
patients have an overall 2- to 5-fold increased risk of developing tumors compared to the 
general population (4). Iatrogenic immunosuppression, in combination with lifestyle habits, 
age and concomitant comorbidities deriving from transplantation, play a central role in the 
pathogenesis of these complications, strongly affecting the efficacy of immunosurveillance in 
these patients. On these grounds, there is the pressing need to better characterize the immune 
dysfunctions related to the immunosuppressive treatment of these patients in order to tailor 
more precisely the therapeutic schedule and decrease the risk of life-threatening 
complications.  
In this study, peripheral blood samples from 73 patients who underwent a several solid 
organ transplant were examined and analyzed. Patients enrolled since 2014 in an oncological 
surveillance study activated at the Centro di Riferimento Oncologico (CRO) in Aviano (PN), 
have been monotorized to prevent and/or diagnose the onset of de novo tumors. Of these, 15 
patients developed de novo cancer during cancer surveillance. By comparing the two cohorts 
we tried to give a predictive, as well as pathogenetic meaning of the results obtained during 
viro-immunological immunomonitoring. 
 
1.1.2 Immunosuppressive therapy in solid organ transplantation 
Immunosuppression is a pharmacological treatment based on the administration of 
immunosuppressive drugs capable of inhibiting the immune system's response to non-self 
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antigens.  Transplant recipients must take immunosuppressive drugs for the rest of their lives 
to prevent allograft rejection. Different types of immunosuppressive drugs are available, but 
in this thesis work we focused on the two main classes currently used in therapy: calcineurin 
inhibitors (CNI) and mTOR inhibitors (mTORi).  
Calcineurin is a calcium/calmodulin-activated serine/threonine phosphatase that, once 
stimulated, de-phosphorylates and thereby activates members of the nuclear factor of 
activated T cells (NFAT) transcription factor family (5). Upon activation, NFAT family 
members migrate into the nucleus and activate transcription (6). NFAT includes a family 
of transcription factors involved in regulating immune response. Calcineurin 
dephosphorylates the cytoplasmic subunits of the NF-AT1 transcription complex (7), which 
are encoded by four genes (NF-ATc1-4) and which undergo nuclear translocation upon 
activation (8). CsA binds directly to the members of the NF-ATc family, dephosphorylates 
serine within SP (SP1 to SP3) repeats and the serine-rich region NF-ATc molecules, which 
then move into the nucleus where they are retained by the persistent elevation of intracellular 
Ca2
+
 and continuous CsA activity (9–11). Calcineurin is also responsible for the transcription 
of the genes encoding for IL-2 and several other cytokines, including TNF-α and IFN-γ. 
CNIs, such as Cyclosporine A (CsA) (1970-80) and Tacrolimus (TAC) (1990), exert their 
immunosuppressive action through the inhibition of the Calcineurin pathway, inducing the 
activation of NFAT, which down-regulates IL-2 and INF-γ expression, and inhibits T-cell 
activation and proliferation in response to foreign antigen (12).  CsA  is a cyclic 
endecapeptide isolated in 1971 from the fungus Tolypocladium inflatum (13), commonly used 
to prevent rejection of liver, heart and kidney transplants. TAC also called FK-506, is a 
macrolide antibiotic isolated from Streptomyces tsukubaensi. The use of this drug was 
initially restricted to patients with liver transplantation, but, more recently, it was also 
extended to patients with heart, pancreas and kidney transplantation (14,15).  
mTORi are a large class of drugs that inhibit mTOR, a serine-threonine kinase involved 
in cell growth, proliferation, protein synthesis and apoptosis (16,17). The PI3K/Akt/mTOR 
pathway is often up-regulated in various malignancies. mTOR is a catalytic subunit of two 
functionally distinct molecular complexes called mTORC1 and mTORC2. mTORC1 is 
composed of five proteins, mTOR, RAPTOR, mLST8, PRAS40 and FKBP38, and the 
complex performs its function by phosphorylating the p70S6 and 4E-BP1 kinases, thereby 
regulating the expression of proteins that promote cell proliferation and survival, such as c-
Myc, cyclin D1, and STAT3. The mTORC2 complex includes RICTOR, MAPKAP1, 
PRR5/PRR5L, Mlst8 and Deptor. mTORC2 directly phosphorylates Akt and regulates the 
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organization of actin cytoskeleton by phosphorylating PKC-α. Unlike mTORC1, which is 
sensitive to acute treatment with rapamycin (RAPA), mTORC2 is less sensitive to this drug, 
although chronic treatments were shown to disrupt the integrity and function of this complex 
(18). The mTORi Everolimus (EVR) was derived from Sirolimus (SRL) and both compounds 
bind to the FK506-binding protein 12 (FKBP12) in the cytoplasm. mTORi have both 
immunosuppressant and anticancer activity, promoting T-cell anergy by compromising DCs 
maturation into antigen presenting cells (APCs) (19). 
 
1.2 Clinical implication of immunosuppressive therapies 
 
1.2.1. Viral infection/reactivation and cancer development 
Since life-long chronic immunosuppression is necessary to preserve allograft function 
in transplanted patients, it is not surprising that opportunistic viral infections are among the 
most common side effects of immunosuppressants. Viral infection or reactivation can occur at 
any time after transplantation; in particular, CMV, Epstein-Barr virus (EBV), Polyomavirus 
BK (BKV) and Human papillomavirus (HPV) virus infections/reactivations occur more 
frequently within a few months after organ transplantation. CMV infection can be easily 
prevented by specific prophylaxis, while EBV or BKV reactivations can only be prevented by 
reducing immunosuppression. Some viral infections may result in post-transplant 
lymphoproliferative disorders (EBV), or Kaposi's sarcoma (human herpes simplex virus type 
8/Kaposi sarcoma herpesvirus), or carcinoma of the skin and anogenital region (HPV). 
Therefore, it becomes essential to better understand the effects of immunosuppressive drugs 
on oncogenic and non-oncogenic virus infections and reactivations, to more precisely define 
the relative level of risk of cancer development in these patients. 
Human CMV infection and reactivation are major causes of morbidity in transplanted 
recipients. CMV belongs to the β-herpesviruses family and is latently present in the majority 
of the general population, being detected in peripheral blood monocytes of 50-90% of healthy 
individuals worldwide. The first correlation between CMV subclinical infection and graft 
prognosis has been reported in a study of over 400 kidney transplants, which showed that, in 
the absence of antiviral treatments, CMV infection, even at subclinical level, was associated 
with increased risk of cardiovascular disease and death. The same study also demonstrated 
that subclinical presence of CMV infection in the first 100 days after transplantation increases 
the risk of subsequent organ rejection (20,21). Usually, CMV-related disease after liver 
transplantation appears as fever and bone marrow suppression and accounts for 60% of CMV 
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diseases in this setting. It may also occur as a gastrointestinal disease and accounts for more 
than 70% of invasive tissue CMV disease in patients with liver and other solid organ 
transplants (22). In a case-control study, Bond et al (23) demonstrated that increased serum 
levels of TAC were not associated with the detection of CMV DNA by PCR, treatment 
regimen, or death, whereas the elevated serum level of CsA significantly correlated with 
CMV-positive PCR, increasing the need for treatment, but without increasing the risk of 
death. This study is of particular relevance because it was carried out to better understand the 
possible pathogenic role of CMV infection in patients undergoing cardiac transplantation with 
the final goal to tailor the immunosuppressive treatment. The data obtained confirmed the 
results reported by a Spanish study carried out in 95 transplanted patients that showed lower 
rates of CMV infection in the group treated with TAC as compared to patients treated with 
CsA (24). The antiviral properties of mTORi have been ascribed to a variety of mechanisms, 
in particular involving memory T cells (25). In a meta-analysysis, Webster et al (26) 
examined a kidney transplant cohort treated with mTORi and showed that the treatment was 
related to a reduction of 51% of CMV infection compared to antimetabolite plus CNI. A 
recent study showed that patients receiving mTORi have a lower risk of CMV disease, and, 
interestingly, when these drugs were combined with Calcineurin, CMV infection was 
controlled more efficiently. Furthermore, Havenith et al (27) demonstrated that patients 




 T cells 
compared with patients included in other treatment regimens. Moreover, the persistent 
stimulation of T cells by latent viruses, such as CMV, can determine the activation of effector 
mechanisms of memory T cells with progressive loss of co-stimulatory molecules (CD28) 
(28) and loss of replicative capacity (CD57 , PD-1, Tim3) (29). This process can culminate in 
the production of un-reactive and poorly functional T cell clones, facilitating evasion from 
non-self immune-surveillance (30,31). 
EBV is a DNA virus belonging to the Gammaherpesvirinae family, responsible for 
infectious mononucleosis and involved in the genesis of lymphoproliferative disorders and 
some epithelial tumors (32). After EBV infection of B lymphocytes, the viral DNA persists in 
these cells in two forms, the episomal and, less frequently, the integrated form. Only in this 
latter case viral DNA is effectively incorporated in host's genome (33). Host immunity plays a 
crucial role in controlling EBV infection and the virus has evolved an elegant strategy that 
allows EBV to exploit B-cell differentiation to finally establish an asymptomatic latency in 
resting memory B lymphocytes. In post-transplant patients, impaired immunosurveillance 
against EBV may favor the onset of EBV-associated lymphoproliferative disorders, the so-
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called post-transplant lymphoproliferative diseases (PTLDs). PTLDs is a heterogeneous 
clinical and pathologic group of lymphoid disorders that may represent an important cause of 
morbidity and mortality in the transplant setting. The first case of PTLD has been diagnosed 
in 1968 by Doak et al. in a kidney transplant (34). The incidence of PTLD in SOT recipients 
is increased 50-120 % compared to the general population (35). The risk of developing PTLD 
is lower in kidney (36) and liver (37) transplants than in other transplant types. Several factors 
play an important role in the development and malignant progression of these diseases, 
including viral infections, strength and duration of immunosuppression, age and even genetic 
factors (38). In adults, PTLDs represent the second more frequent group of post-transplant 
neoplasms after those of the skin, while they are the most common malignancy in organ 
transplanted pediatric patients. After transplantation, the EBV genome is found in 60-70% of 
B cells (39), the primary target of EBV infection. The immune response to EBV infection 
involves both innate and adaptive immunity mainly mediated by cytotoxic T lymphocytes 
(CD8
+
) and NK cells (40). Symptomatic infection, mainly occurring during infectious 
mononucleosis, is associated with increased numbers of NK cells in peripheral blood, which 
may exert cytotoxicity against infected B cells and enhance the antigen-specific T-cell 
responses through the release of immunomodulatory cytokines (41). In immunosuppressed 
transplant patients, mainly pediatric, primary EBV infection is poorly controlled, finally 
resulting in the development of EBV-associated PTLDs. Considering that the ability to 
control EBV replication and expansion of EBV-infected B cells strongly depends on the 
number and the efficacy of EBV-specific T cells, it is clear that in SOT patients this response 
may be hampered by immunosuppressive regimens, increasing the risk of PTLD. 
Consistently, the risk of EBV-associated PTLD is increased when an EBV-seronegative 
patient receives a transplant from an EBV
+
 donor (42) and this mainly occurs in pediatric 
patients. The most common malignant PTLD subtype is post-transplant large B-cell 
lymphoma (PT-DLBCL), followed by Burkitt lymphoma (PT-BL) and plasmablastic 
lymphoma (PT-PBL) (43), while Hodgkin lymphoma (HL) is a rare form of PTLD (44). The 
disease presentation is often nonspecific and may also involve the transplanted organ in about 
half of cases (45). Notably, early-onset PTLDs, usually occurring within the first year of 
transplantation, are almost always EBV
+
 and treatable with a decrease in the dose of 
immunosuppressants (46). On the contrary, late-onset PTLDs in adult renal allograft 
recipients are more frequently EBV-negative and more difficult to treat.  Pivotal studies, 
conducted by Tanner JE et al (47) showed that transplanted patients undergoing 
immunosuppressive therapy with CsA had an increased incidence of EBV-associated PTLDs. 
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Notably, these patients had increased serum levels of the B-cell growth promoting cytokine 
IL-6 probably due to the direct role of CsA in inducing EBV lytic cycle in infected B cells. 
Chen et al (48) also demonstrated that in vitro CsA is also able to promote the EBV-driven 
immortalization of primary B cells. Moreover, post-transplantation treatment with RAPA was 
shown to reduce the ability of B cells to undergo EBV lytic cycle replication (49), whereas the 
combination of mTORi and inhibitors of HSP90 (a dysregulated protein in EBV-related 
PTLDs) had a synergistic effect in inducing apoptosis and in vitro cytotoxicity of EBV-
positive cells (50). Conversely, a reduction in the efficacy of EVR treatment has been shown 
when the mTORi are used in combination with TAC in EBV-positive cell lines (51).  
Non-melanoma skin cancers are the most common malignancies observed after SOT, 
occurring in more than a half of recipients (52). The pathogenesis of these tumors is 
multifactorial being the result of the complex interplay of the effects of ultraviolet radiation, 
compromised immune surveillance, direct effects of immunosuppressive drugs and infection 
by oncogenic viruses. With regard to the potential risk conveyed by immunosuppressants, 
metabolites of AZA were shown to interact with UVA to generate oxygen species, causing 
DNA damage and protein oxidation, resulting in mutagenic effects in the skin (53,54). CNIs 
may also cooperate with UVA and UVB in increasing the levels of TGF-β and suppressing 
p53 expression through the induction of ATF3 (55). SOT recipients are 250 times more 
probably to develop non-melanoma skin cancer and treatment with mTORi has been 
associated with reduced cancer incidence (56). Cutaneous squamous cell carcinoma (SCC) is 
the predominant skin cancer in SOT patients and its occurrence is 65-250-fold higher 
compared to that of the general population (57). Squamous differentiation of tumor cells, 
increased mitotic rates and ulceration are frequent features of these carcinomas (58). 
Conversion from CNIs to SRL was shown to reduce the vascularization of SCC in SOT 
patients (59). Basal cell carcinoma (BCC) is the second most frequent cancer in these patients 
and, among the numerous histologic variants of this tumor, nodular BCC is the most common 
(60). Surgical excision is the first-line therapy for BCC and the occurrence of distant 
metastases is rare. Skin tumors in transplanted patients are often associated with the presence 
of oncogenic viruses, in particular HPV. Human papillomavirus is a double-stranded non-
enveloped DNA virus which infects skin and mucosal keratinocytes (61). HPV infection is 
responsible for the development of viral warts that can cause significant morbidity in 
immunosuppressed individuals. In HPV-positive transplanted patients, lifelong 
immunosuppressive therapy with mTORi has been associated with a significant reduction in 
the incidence of de novo neoplasms (62).  Available data show that the presence of HPV 
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infections, in particular by β-HPV, increases the risk for the development or progression of 
skin tumors up to 30%. HPV has a strong tropism for keratinocytes but the mechanism 
through which the virus infects these cells has not been clarified yet. The persistent presence 
of HPV predisposes mainly to BCC, although the virus is also detectable in SCC (63,64). 
Dharancy et al (65) reported the case of a young liver transplant patient in whom the 
conversion to SRL therapy was followed by a rapid regression of skin warts, suggesting that 
mTORi may be beneficial in immunosuppressed patients with HPV-induced relapsing warts.  
 
1.2.2  Cancer onset and development 
The risk to develop a de novo neoplasm or a tumor relapse in solid OTRs is very high, 
about 2-5 times higher compared to the general population (66) and this is due not only to the 
establishment of oncogenic virus co-infections or reactivations, but also to the duration and 
potency of immunosuppressive drug treatment. The reduction of immune surveillance, 
together with patient lifestyle contributing factors, often lead to the development of aggressive 
tumors. Therefore, although pharmacologic immunosuppression has the power to inhibit the 
rejection of the transplanted organ, this treatment may have detrimental effects on the 
immune-surveillance efficacy of these patients.  Immune-evasion plays a pivotal role in 
tumorigenesis in transplantation, because in immunocompetent individuals immune-
surveillance controls the development of neoplasia, whereas, in immunocompromised 
individuals, chronic immunosuppression predisposes to a variety of infections and 
reactivations of oncogenic viruses and the control of developing cancers may be severely 
impaired. The mechanisms that drive the onset of de novo tumors in SOTs can be grouped 
into three major categories: 1) direct pro-oncogenic properties of select immunosuppressive 
drugs; 2) increased risk of oncogenic virus reactivations; 3) impaired immune-surveillance of 
tumor cells (67). 
CsA and TAC were found to upregulate vascular endothelial growth factor (VEGF) and 
transforming growth factor-beta (TGF-β), both implicated in cancer progression, 
angiogenesis, invasive phenotypes and uncontrolled cell growth (68–70). Furthermore, the 
use of CNIs can increase the frequency and severity of diseases related to viral 
infection/reactivation, such as those induced by EBV, HPV and CMV, exposing patients to 
increased risks to develop virus-related cancer. CsA can be correlated with cancer 
development, as suggested by Hojo et al, who showed that CsA induces TGF-β secretion 
through a cell-autonomous mechanism. In this study, adenocarcinoma cells treated with CsA 
showed marked morphological and functional alterations, including increased cell motility 
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and invasive growth (71). CNI were also shown to mediate Ras activation and promote renal 
cancer cell proliferation, thus highlighting an additional tumorigenic pathway by which CNI 
promotes oncogenesis. Some studies demonstrated that CsA treatment induces overexpression 
of VEGF in human cell renal carcinoma, an effect that is dependent on Ras activation (72,73). 
Wimmer et al reported that the risk of de novo malignancies is increased in TAC-treated 
patients compared to the CsA treatment (74). DNA repair is also inhibited by CsA, whereas 
TAC was also shown to inhibit DNA repair (75), another possible contributory factor to the 
increased risk of cancer in these patients. Furthermore, the levels of IL-6 were markedly 
increased in EBV-infected cells treated with CsA. This cytokine is capable to promote B cells 
activation and possibly immortalization (47,76). Indeed, the incidence of different types of 
tumors that have developed in transplant patients have been related to the use of CsA. A high 
incidence of cancer was found in kidney transplant recipients treated with high-dose CsA 
(77,78). In addition, the risk of skin cancer is higher in patients treated with CsA and exposed 
to ultraviolet-A light (79). 
mTOR inhibitors were initially designed as anti-cancer drugs, as well as 
immunosuppressive agent, because of their ability to suppress the growth and proliferation of 
tumor cells in mice (80). One of the most important effects of mTORi is inhibition of 
angiogenesis and decreased VEGF synthesis (81).  Dysregulation of cell cycle characterizes 
several types of tumors, and consequently, mTOR became an important therapeutic target for 
cancer patients. Loss of mTOR function leads to an arrest of G1 phase of the cell cycle and a 
severe reduction of protein synthesis (82), demonstrating that the mTOR pathway is crucial 
for cell survival and protein synthesis. In fact, the hyperactivation of the mTOR/PI3K/AKT 
pathway may be detectable in virtually all types of tumors. The most common mechanism 
resulting in aberrant PI3K signaling is somatic loss of PTEN, which is mutated or 
epigenetically inactivated in an large number of cancers (83). Akt is a cytosolic protein that 
phosphorylates different substrates, such as the proapoptotic factors Bad and procaspase-9, 
and is able to induce the expression of Fas ligand. Furthermore, Akt phosphorylation is 
involved in the induction of NF-kB transcriptional activity and in the decrease of p53 levels 
through the phosphorylation of the transcription factor Mdm2. Therefore, through the 
modulation of different biochemical pathways, Akt promotes cellular survival and resistance 
to apoptosis. Several studies have found Akt overexpression in gastric, ovarian, pancreas, 
breast and stomach cancer (84).  
Noteworthy is the effect that RAPA has on the immunosuppressive regulatory T cells 
(Tregs). A study conducted in rats investigated the in vivo effects of RAPA, showing that 
12 
 







 Tregs, which play an indispensable role in inducing 


















 T cells are resistant to apoptosis and 
are dependent of IL-2 signaling for expansion and survival. In addition, RAPA may synergize 
with retinoic acid in the generation and activity of Tregs because retinoic acid promotes the 
expression of β7 integrin, a subunit of α4β7 integrin, while RAPA enhances the expression of 
CXCR4, a potent chemokine receptor for lymphocytes (87). Furthermore, a recent study has 
shown how the conversion from CNI to SRL in kidney transplants has reduced the incidence 
of skin tumors, one of the most frequent types of cancer (88).   
 
1.3 Immune system and immunosuppression  
In a normal state of immunocompetence, cells of the innate immune system, such as 
APCs, must differentiate from an immature to a mature state to allow the initiation of specific 
T-cell responses. DCs constitute a heterogeneous population of APCs that mediates critical 
connections between innate and adaptive immunity (89). These cells play a pivotal role in 
antigen processing and presentation resulting in the induction of effective immune responses 
against pathogens and tumor cells. Notably, these cells are the most powerful APCs, being 
able to orchestrate a primary immune response but also to induce immune tolerance (89).  In 
particular, DCs play a central role in priming naive T and B cells, the first critical steps in the 
induction of an antigen-specific immune response. DCs develop from CD34
+
 bone-marrow 
progenitor cells or from CD14
+
 monocytes and differentiate into iDCs, which are functionally 
specialized to take up exogenous antigens. After recognition, exogenous antigens are 
internalized and the activated DCs migrate to the draining lymph node, where they can induce 
an adaptive immune response (90). This successful outcome requires the processing of a 
antigens are their loading in the form of small peptides on the main histocompatibility 
complex (MHC) molecules. Peptides loaded on MHC-II molecules may be recognized by 
antigen-specific CD4
+
 T helper cells, while peptides loaded on MHC-I molecules may be 
recognized by antigen-specific CD8
+
 T lymphocytes. The presentation of internalized 
antigens on MHC-I molecules is defined as cross-presentation, a crucial process in the 
induction of effective adaptive immune responses against tumors and viruses that do not 
infect DC directly and that may induce peripheral tolerance (91). The MHC-I pathway is 
normally used to present endogenous antigens and cross-presentation is particularly important 
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because it allows DCs to present through the MHC-I pathway also exogenous antigens, which 
are usually mainly presented by MHC-II molecules (92). The cross-presentation pathways of 
the antigens are essentially two: 1) the vacuolar pathway, in which the processing/loading 
takes place within the endo/lysosomal compartment and 2) the endosome pathway, in which 
the internalized antigens are transported from the endosome to the cytosol where they are 
degraded by the proteasome (93). The co-stimulatory CD40/CD40L axis along with the 
danger signal provided by an exogenous antigen are catalysts for DC licensing. Therefore, 
exogenous antigen cross presentation and the consequent activation of naive CD8
+
 cytotoxic 
T cells, provides the immune system with an important mechanism for generating immunity 
to viruses while preserving tolerance to self (94).  
The goal of immunosuppression is to avoid rejection of the transplanted organ, 
attenuating the immune response to the non-self, but as widely discussed earlier, this may 
result in the loss of functional immune surveillance in transplanted patients, thus facilitating 
the development of viral infections and the development of de novo tumors. 
Immunosuppressive therapies have an impact on all the compartments of the immune system, 
such as Natural Killer Cells (95,96), B lymphocytes (97,98) , Macrophages (99,100) and 
Myeloid-derived suppressor cells (101) In this thesis work, the attention is directed in 
particular to the impact of the immunosuppressive regimens on DCs and T cells. 
 
 
1.3.1 T lymphocytes and DCs  
T lymphocytes are cells derived from a pluripotent stem cell of the bone marrow and 
matured in the thymus and represent fundamental mediators of adaptive immune responses. T 
lymphocytes have a specific antigen receptor called T-cell receptor (TCR), associated to a set 
of molecules that form a structural unit, known as CD3 complex. T cells are dived in two 
major family: CD4
+
 T cells and CD8
+
 T cells. CD4
+
 T cells perform multiple functions, 
ranging from the activation of cells of the innate immune system, B cells, cytotoxic T cells 
and suppression of the immune reaction. Several studies have continuously identified new 
subgroups of CD4
+
 cells in addition to the classic T-helper cells 1 (Th1) and T-helper 2 (Th2): 
these include T-helper 17 (Th17), follicular helper T cells (Tfh), induced T-regulatory cells 
(iTreg), the regulatory type 1 (Tr1) cells and the potentially distinct T-helper 9 (Th9) subset. 
The differentiation of different lineages depends on the complex network of specific 
transcription signals mediated by cytokines and transcription factors followed by epigenetic 
modifications (102,103). CD8
+
 T cells  and are very important for immune defence against 
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intracellular pathogens, including viruses and bacteria, and for tumor surveillance. When a 
CD8
+
 T cell recognises its cognate antigen and becomes activated, it has three major 
mechanisms to kill infected or malignant cells. The first is secretion of cytokines, 
primarily TNF-α and IFN-γ, which have anti-tumour and anti-viral microbial effects. The 
second mechanism is the production and relase of cytotoxic granules, wich perforin and 
granzyme, that induce the apoptosis of target cells. The last mechanism is the killing of target 
cells via Fas/FasL interaction, with induction of caspase cascade and apoptosis of target cells. 
(104,105)  





 T cells and CD8
+
 cytotoxic T cells isolated from healthy donors. Similarly, the 
production of TNF-α was also suppressed in the presence of the drug. This work has shown 
that the immunosuppressive activity of TAC also influences the NF-kB signaling and the 
NFAT pathway as well (106). Interestingly, CsA and TAC were shown to prevent naive T-
cell differentiation into cytokine-producing mature cells and inhibit cytokine-production by 
memory CD4
+
 T cells (107). In human peripheral T cells costimulated with simultaneous 
engagement of T cell receptor (TCR)/CD3 and CD28 it has been demonstrated that 10 ng/ml 
CsA inhibited NF-AT and NF-kB migration into the nucleus followed by reduction of T-cell 
proliferation in response to the costimulation (108). Available data indicate that the 
conversion from TAC to SRL suppresses Th17 activity and up-regulates the percentage of 
Treg cells in kidney transplant recipients. SRL inhibited Ser705 phosphorylation of STAT3 in 
CD4
+
 T cells, which promotes a differentiation switch towards Treg cells rather than to Th17 
cells. A possible activation of STAT5 by SRL, which has an opposite effect to STAT3, was 
also suggested. The drug was also shown to induce a downregulation of IL-17 and an 
increased expression of Foxp3 in Th17 cells. Therefore, the conversion from TAC to SRL 
favorably regulates the Th17/Treg ratio (109). A recent study investigated the contribution of 
residual immune function in mediating the decreased incidence of SCC showed by 
renal transplant recipients switching CNI-based therapies to mTORi. While both RAPA and 
TAC enhanced the survival of OVA-expressing skin grafts, and inhibited short-term antigen-
specific CD8
+
 T cell responses, RAPA but not TAC induced a significant infiltration of 
CD8
+
 effector memory T cells into UV-induced SCC lesions. Moreover, only RAPA was able 
to increase the number and enhance the function of CD8
+
 effector and central memory T cells 
in a model of long-term contact hypersensitivity. These findings are consistent with the 
possibility that the lower risk of de novo SCC showed by patients switched to mTORi 
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regimens is probably due to enhanced CD8
+
 memory T cell responses to new antigenic 
stimulations occurring in their skin (110). 
Treatments with RAPA was shown to inhibit the differentiation of antigen-specific 
CD8
+
 T cells in vivo, while increasing the number of CD8
+
 memory T cells. In fact, RAPA 
promotes the generation of long-lived memory precursors by altering the process of 
development of short-lived precursors (111,112). These findings are consistent with the 
observation that the treatment of mice with RAPA following acute lymphocytic 
choriomeningitis virus infection improved not only the quantity but also the quality of virus-
specific CD8
+
 T cells and also improved the response of memory T cells in non-human 
primates after vaccination with a modified vaccinia virus-Ankara (25). Because of their strong 
immunosuppressive properties, Tregs have been intensely studied for their use in cell 
therapies, as they maintain tolerance against self-antigens and abort excessive immune 
responses. Treg cells are principally characterized by expression of CD25 and FoxP3 and 
represent 5-10% of all peripheral CD4
+














)(114). Their mechanism of action involves immunosuppressive activities 
against other T cells, B cells, macrophages, DCs and NK cells and the release in the 
microenvironment of immunosuppressive cytokines such as IL-10, IL-35 and TGF-β to 
prevent T-cell proliferation and maturation of antigen presenting cells (115). Treg cells may 
also secrete granzymes and perforins (116) and express CTLA-4, which may de-regulate the 
activity of DCs (117). The pilot study by Levitsky et al. has shown that, in liver transplant 
patients, monotherapy with SRL resulted in a higher percentage of Tregs in peripheral blood 
compared to non-SRL monotherapy (118). In fact, the expression of FoxP3 requires IL-2, 
whose gene transcription is blocked by CNI but not by SRL. These data were confirmed in a 
subsequent work that showed that RAPA, but not CsA, does not inhibit the function of Treg 
cells but rather promotes their induction (119). 
A recent study in kidney transplant recipients investigated the correlation between the use 
of immunosuppressants, sun exposed (SE) skin and the onset of skin tumors. In particular, the 
treatment with SRL significantly increases the absolute number of CD4
+
 T cells, memory 
CD8
+
 and CD4+ T cells, and Treg cells in the blood of patients with SE skin compared to 
those with non-SE skin (120). RAPA was also found to eliminate antigen-specific effectors 
CD8
+
 T cells and expand Tregs. In fact, in mouse models used to test the efficacy of RAPA 
and CsA as a therapy for immune-mediate bone marrow failure (such as aplastic anemia) it 
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has been shown that that RAPA reduced the proportion of memory and effector T cells and 
maintained a pool of naïve T cells (121).   
Immunosuppressive drugs employed in the management of allograft rejection in SOT 
patients can also influence the phenotypic and functional characteristics of DCs, suggesting 
that their impaired function may also play a role in the development of tumors or in 
promoting the reactivation of viral infections in immunosuppressed patients. 
DCs exist in two differentiation states, each of which has distinct phenotypic, 
morphological and functional characteristics: iDCs and mature dendritic cells or mDCs. iDCs 
phenotypically show high expression of CCR1, CCR5, CCR6 and CD68, while the expression 
of CCR7, CD86, CD80, CD40 and CD83 is low. They are able to capture and process the 
antigens they encounter and subsequently evolve to mDCs, which are characterized by high 
expression levels of CD83, CD86, CD49, CD80, CCR7, MHC-II, CD1a and CD11c (122). 
Another classification of DCs is based on different DC subpopulations: classical DCs (cDCs), 
plasmacytoid DCs (pDCs), monocyte-derived DCs (moDCs) and Langherans cells (LCs).   
The effects of CNIs on DCs are well recognized and several groups have investigated 
the impact of these drugs on mouse and human DCs. TAC and CsA were found to inhibit the 
allostimulatory capacity of in vitro-generated myeloid DCs without affecting DC maturation 
(123). On the contrary, the pioneering work of Lee et al has shown how the treatment with 
CsA impaired the allostimulatory capacity of in vitro generated mouse BM-derived DCs by 
downregulating CD40, CD80, and CD86 expression associated with reduced nuclear 
translocation of NF-κB, a transcription factor promoting DC maturation (124,125). In 
addition, CsA inhibited DC-dependent production of INF-γ, IL-2 and IL-4 by T cells, and IL-
6, IL-12p40 and IL-12p70 by DCs (126). Recently, it was demonstrated that DCs generated in 
the presence of CsA lose their ability to induce Treg cell proliferation, with a strong reduction 







 T cells (127), thus having a negative impact on this population (128). 
Moreover, TAC was shown to inhibit the ability of DCs to stimulate T cells and to decrease 
the production CXCL10 and IL-12. Although IL-12 production by DC was impaired by TAC, 
these cells did not promote Th2 development as T cells stimulated by TAC-treated DCs 
produced less interferon IFN-γ, IL-4 and IL-10 (129). 
In mouse models, RAPA strongly impacts DC maturation and function resulting in the 
induction of well-defined phenotypic characteristics of these cells. Data accumulated so far 
indicate that RAPA is able to impair maturation of DCs, reduce DC costimulatory molecule 
upregulation, decrease the production of pro-inflammatory cytokines, inhibit T cell 
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stimulatory capacity (130) and promote the selective development  of Treg cells in animal 
models of solid organ transplantation (131). Mouse and human DCs treated with RAPA have 
an immature phenotype with low levels of CD80 and CD40 receptors and with a decreased 
expression of B7-H1, the PD-L1 ligand, a negative regulator of T cells activation and inducer 
of peripheral tolerance (132). In both mouse and human DCs, a reduced expression of CCR7 
was observed after treatment with RAPA, an effect that may decrease the ability of DCs to 
migrate to draining lymph nodes. In an elegant study, Sordi et al. showed how the use of 
immunosuppressive drugs may interfere with the generation of effective immune responses by 
affecting DC function (133). In particular, these Authors investigated the functional relevance 
of chemokine receptors in the process of DC maturation both in vitro and in vivo. During the 
maturation process, DCs downregulate the CCR1 and CCR5 receptors and upregulate the 
expression of CCR7, which promotes the DCs migration from the peripheral tissues to the 
sites where they will encounter the naive T cells for their priming. CsA and TAC were shown 
to slightly modulate the expression of CCR7 but without affecting the function of this 
chemokine receptor. In contrast, RAPA increased the expression of CCR7 at the mRNA and 
protein level and enhanced the in vitro migration of human DCs to CCL19 and of mouse DCs 
to lymph nodes in vivo. Experiments carried out in LPS-maturing DCs suggested that these 
effects could be related to the ability of RAPA to inhibit autocrine IL-10 production. RAPA-
treated alloantigen-pulsed DCs were shown to induce antigen-specific regulation and prolong 
experimental heart allograft survival. Taner et al. demonstrated that RAPA-exposed DC 
loaded with donor cell lysates and their adoptive infusion prior to experimental heart 
transplantation prolonged fully MHC mismatched murine heart allograft survival (134). 
Notably, RAPA-treated DCs were also shown to stimulate the generation of antigen-specific 
Foxp3
+
 Treg cells thereby promoting organ transplant tolerance (135). The induction of 
tolerance by RAPA is further enhanced by the combination with Flt3L, which promotes the 





 Treg cells and IL-10 secretion (136).  
T cell responses are modulated by cytokines secreted by mDCs including pro-
inflammatory cytokines, such as IL-12 and INF-α, and anti-inflammatory cytokines, such as 
IL-10. DCs treated with RAPA have a distinct cytokine secretion profile at different stages of 
maturation. In iDCs, RAPA reduced IL-10 and IL-12 production after LPS stimulation and 
increased apoptosis, while mDCs are resistant to RAPA-induced apoptosis, but they also 
show decreased production of IL-10 and TNF-α (137). A recent study demonstrated that 
relevant concentrations of RAPA (20 ng/ml) inhibit the ability of both TLR7- and TLR9-
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activated pDCs to stimulate the production of IFN-γ and IL-10 by allogeneic T cells. On the 
contrary, RAPA-treated TLR7-activated pDCs were capable of stimulating the activation of 




 Treg cells (138). 
 
1.3.2 NF-kB transcription factor  
NF-kB  is a protein complex that functions as a transcription factor and has a critical 
role in the regulation of the immune response during infections and inflammatory processes. 
NF-kB represents a group of structurally related and evolutionarily conserved proteins that 
belong to the Rel family and are regulated via shuttling from the cytoplasm to the nucleus in 
response to cell stimulation (139).  In the absence of stimulation, the NF-kB complex 
composed of Rel and p50 protein subunits is in an inactive state in the cytosol, due to the 
binding with inhibitory proteins IkBa, IkBβ and IkBε. Different signals favor the activation of 
NF-Kb with consequent phosphorylation of IkB inhibitors from κB kinase (IKK) complex, 
composed of the kinases IKKα, IKKβ and the regulatory subunit NEMO (IKKγ). Activation 
of the IKK complex requires K63-ubiquitination of the regulatory subunit NEMO/IKKγ 
(140). When NF-kB  is freed from this complex is made available for translocation into the 
nucleus where it  may activate the transcription of several immune-related genes (141). One 
of the main roles of NF-kB is to antagonize apoptosis, promoting cell survival by inducing the 
expression of pro-survival genes (Bcl-2, Bcl-xL, IEX1) and repressing the pro-apoptotic 
genes (Bax and Bim) (142,143). Since the OTRs have an altered immunological function, the 
evaluation of the transitional state of the transcription factor NF-kB in T cells and in DCs 
could represent an index of functional intregrity of the immune system of these patients. The 
effects of CNI and mTORi against the nuclear translocation of NF-kB are known. In fact, as 
already described above, the pioneering works of Vadafari et al (106) and Lee et al (124) have 
shown how CNI reduced nuclear NF-kB translocation in T cells and DCs, respectively. NF-
kB persistence in the cytoplasm in phosphorilated form may prevent the transcription of pro-
inflammatory cytokines, such as IL-12 and IFN-γ, and the inhibition of specific T-cell 
responses (106). Furthermore, the inhibition of mTOR regulates negatively signaling in 
moDCs, potentially leading to the differential phenotypes observed in moDCs (132) . In 
addiction, in human myeloid moDCs, the inhibition of NF-kB during differentiation and 
activation has been shown to be associated with apoptosis due to caspase 3 induction and loss 
of mitochondrial transmembrane potential, demonstrating that this pathway is essential for the 




The final goal of this study is to improve the current strategies of cancer surveillance for long-
term immunosuppressed patients with the identification of an immunologic profile potentially 
able to more reliably estimate the risk of de novo malignancy in OTRs. This is highly relevant 
considering the central role of immunosurveillance in the control of nascent tumours and the 
increasing numbers of OTRs living and aging after transplantation.  
The specific aims of this project are: 
 
1) To assess whether the occurrence of oncogenic viral reactivation or de novo cancer 
development correlates with measurable changes in the levels of T-cell responses 
specific for oncogenic viruses and/or tumor-associated antigens.  
2) To assess the impact of chronic immunosuppression on the impairment of anti-tumor 
immune responses through functional analyses of immune cell activation status carried 
out during the clinical follow-up. 
3) To identify an immunologic profile predictive of increased risk of tumor development 
and viral reactivation in SOTs.  
 
In particular, the study aims to identify and validate, through multiparametric investigations, 
the potential predictive role of immunological biomarkers, such as CD4 and CD8 T-cell 
specific immune responses against viral and tumor-associated antigens; furthermore, the 
activation status of effector cells and DCs and the levels of TERTmRNA in the plasma 
samples will be also investigated as additional markers of the level of retained immune 
proficiency in SOT recipients. 
The study takes advantage of the immunosurveillance protocol for SOT recipients activated at 
the Centro di Riferimento Oncologico (CRO) in Aviano (PN), which includes a clinical 
surveillance program focused on the most frequent and diagnosable De Novo tumors with 
standardized screening (skin, lung, kidney, rectum, cervix and pharynx carcinomas) with 










3.1 Patients characteristics and immunosuppressive regimen 
Globally, since 2014, 111 patients were enrolled in our immune-monitoring protocol, of 
whom 73 were considered evaluable for the study, on the basis of the availability of at least 
two serial samples for analysis. 57 patients had received kidney transplantation, 8 heart 
transplantation, 4 liver transplantation, 3 kidney+kidney transplantation and 1 heart+kidney 
transplantation. Among these patients, 2 were treated with AZA, 55 with CNI, 7 with mTORi 
and 9 with CNI+mTORi. According to the guidelines of the surveillance protocol, patients at 
high risk (HR) of tumor onset have had intensive surveillance every2 to 6 months based on 
the target organ. For low risk (LR) patients, a non-intensive surveillance is performed 
annually, with a program screening similar to that of the general population. During 
surveillance, 15 patients were diagnosed with a de novo tumor: 9 BCC, 4 SCC, 1 in situ 
melanoma and 1 kidney tumor.  This group include 12 kidney transplants, 1 heart transplant 
and 2 double transplants. “Tumor” patients had an average of 69 years and 14 years of 
immunosuppression. 73% of these patients were treated with CNI, 20% with CNI+mTOR and 
7% with mTORi. Their clinical characteristics are summarized in Table 1.  
Tumor-free patients had an average age of 60 years and 16 years of immunosuppression, and 
include 43 kidney transplants, 7 heart transplant, 4 liver transplants and two kidney+kidney 
double transplants. 74% of these patients were treated with CNI, 10% with mTORi and CNI + 
mTORi respectively and and the remaining 17% with AZA. 
 
Table 1. Clinical characteristics of SOT tumor cohort 
Patient Age Age of 
transplant 
Years of IS Transplantated 
organ 
Type of IS Type of 
tumor 
HR LR 
SOT 04 82 55 and 73 27 Heart+kidney CNI+mTOR BCC yes no 
SOT 07 69 62 7 Kidney  CNI BCC yes no 
SOT 08 60 29 31 Kidney CNI BCC yes no 
SOT 11 64 58 6 Kidney CNI Kidney yes no 
SOT 14 67 60 7 Kidney CNI+mTOR SCC yes no 
SOT 34 70 45 25 Kidney CNI Melanoma in 
situ 
yes no 
SOT 35 57 41 16 Kidney CNI BCC yes no 
SOT 37 73 65 8 Kidney CNI SCC yes no 
SOT 40 62 57 5 Kidney+kidney CNI+mTOR BCC yes no 
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SOT 43 63 49 14 Kidney mTOR BCC yes no 
SOT 49 70 55 15 Heart CNI BCC yes no 
SOT 80 82 68 20 Kidney CNI BCC yes no 
SOT 83 59 50 9 Kidney CNI SCC yes no 
SOT 89 76 62 14 Kidney CNI SCC yes no 
SOT 98 80 73 7 Kidney CNI BCC yes no 
 
 
3.2 Detection of viral and tumor epitope-specific T-cell responses in SOT patients  and 
healthy donors   
Tumor and viral antigen-specific T-cell responses were comparatively assessed in two 
cohorts: “tumor” cohort with a de novo tumor occurred during surveillance (n=15 patients), 
and  a “no tumor” cohort (58 patients). For all these patients, samples taken at baseline and 
during follow-up/diagnosis were available. For the first group, we chose as reference the 
sample taken as close as possible prior to the time of the diagnosis of cancer (± 4 months from 
the diagnosis). T-cell responses against pools of peptides were assessed by IFN-γ ELISpot 
assay (interferon-γ-Enzime linked immunosorbent Spot) in samples from all 73 patients and 
from 9 healthy donors.  
 
3.2.1 T cell responses against Tumor Associated Antigens (TAAs) 
T-cell responses to 2 “universal” TAA-derived peptides mix (Survivin and hTERT) were 
evaluated in un-stimulated PBMCs by IFN-γ ELISpot assay in 9 healthy donors as control and 
in 65 patients at baseline and at one follow up time point. To investigate the correlation 
between the extent of spontaneous T-cell responses against TAAs and the tumor onset, we 
divided our patients into two cohorts: 15 patients with cancer occurred during surveillance 
and 50 tumor-free patients. As shown in Figure 1A, the levels of T-responses specific for 
hTERT detected at baseline (prior to tumor development) in the “tumor” cohort were 
significantly lower compared to those observed at the time of the diagnosis of cancer. The 
level of hTERT-specific T-cell responses was higher at the time of diagnosis of cancer in the 
“tumor” cohort compared to the levels observed at the baseline in the “no tumor” cohort and 
in healthy donors. No significant differences were observed between to the values observed at 
baseline and follow up in the “no tumor” cohort and as compared to those detected in healthy 
donors (Figure 1A). Similarly, the levels of T-cell responses against Survivin at the time of 
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diagnosis of cancer in the “tumor” cohort were significantly higher as compared to those 
observed  before the onset of the tumor in the same group. In addition, also the levels of 
Survivin-specific T-cell responses observed at the time of follow up in “no tumor” cohort  
were significantly higher than those of healthy donors. We also detected significantly higher 
levels of Survivin-specific T-cell responses at follow up in the “no tumor” cohort as compared 
with those of healthy donors (Figure 1B). Table 2 summarizes the mean and median values of 




Table 2. Spontaneous T cell responses against TAAs in SOTs 
   “Tumor” cohort  “No Tumor” cohort  Donors 
   Baseline  Diagnosis  Baseline  Follow up   
hTERT Mean  89  90  19.5  41.74  9 
SD  306  138  39  88  5 
Median  9  20  9.5  15  8 
Survivin Mean  44  210  53.2   61.94  7 
SD  131  358  158  167  4 
Median  10  11  8  15  7 
TOT pts   15  50  9 
 
 
 B Tc vs 
D Tc 
B Tc vs B 
NTc 
B Tc vs F 
NTc 
B Tc vs d D Tc vs 
B NTc 
D Tc vs F 
NTc 
D Tc vs  
d 
B NTc vs 
F NTc 
B NTc vs 
d 




0.026* 0.960 0.238 0.834 0.006* 0.854 0.010* 0.066 0.984 0.194 
P-values 
Survivin 
0.142 0.837 0.153 0.509 0.434 0.535 0.049* 0.057 0.674 0.036* 







Figure 1. Spontaneous T cell responses against TAAs in SOTs. All tests were performed using PBMCs from patients at 
different time point. The number (enumerated as SFC, spot forming cells) of TAA-specific T cells responses was  





3.2.2. Association between TERTmRNA levels in the blood and tumor onset in SOTs 
 
Telomerase is responsible for telomere maintenance in the majority of human cancers, but its 
activity is absent in normal cells. Telomerase consists of two subunits: a functional catalytic 
protein subunit, the human telomerase reverse transcriptase (hTERT) encoded by 
the TERT gene, and a RNA component called human telomerase RNA component (hTERC or 
hTR), encoded by the TERC gene. This specialized DNA polymerase plays a pivotal role in 
carcinogenesis through the maintenance of telomeres (145). Recent evidence indicates that 
quantification of hTERT mRNA in the blood may be a reliable tumor biomarker that may 
correlate with clinicopathological parameters and treatment efficacy. Considering that SOT 
patients who developed a tumor showed increased levels of T-cell responses against hTERT, 
we investigated whether the levels of TERT mRNA in the blood could constitute an early 
marker of tumor development in these patients. On these grounds, circulating cell-free TERT 
mRNA was quantified by real-time PCR (146) in 30 patients at baseline and follow up, 
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respectively. Patients were stratified into two groups: 15 patients with a tumor event and 15 
cancer-free patients during surveillance. In the “tumor cohort” at baseline, the median of 
TERT levels was 61 (0-576, mix and max value respectively; mean=116) copies/ml, while at 
follow up/diagnosis the median value was 56 (0-421, mix and max value respectively; 
mean=102) copies/ ml (p=0.773, not significant). Globally, the levels of circulating TERT 
mRNA were significantly higher in patients who developed a tumor as compared with the 
tumor-free cohort. In particular, in the “no tumor” cohort at baseline, the median of TERT 
levels was 0 (0-88, mix and max value respectively; mean=24) copies/ml and at follow up the 
median was 0 (0-92, mix and max value respectively; mean=25) copies per ml (P=0.918, not 
significant). The level of circulating cell-free TERT mRNA at baseline in the “tumor” cohort 
was significantly higher if compared with circulating cell-free TERT mRNA at baseline of 
“no tumor” cohort (P=0.033). Further, the level of circulating cell-free TERT mRNA at 
follow up of “tumor” cohort was significantly higher if compared with circulating cell-free 





Figure 2. Circulating cell-free TERT mRNA copies. TERT copies/ml for “tumor” and “no tumor”  
cohorts  at  baseline and follow up, respectively. Statistical Analysis was performed with t Student 
  test (*, P<0,05). 
 
Diagnosis Follow up Baseline Baseline 
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3.2.3 T cell responses against Virus antigenic epitopes  
 
T-cell responses in un-stimulated PBMCs to CMV, EBV and HPV peptide mix were 
investigated by IFN-γ ELISpot assay in 5 healthy donors and in 73 patients at baseline and at 
one follow up time point. To evaluate the correlation between tumor onset and viral 
reactivation/infection in patients with cancer, we considered two groups: 15 patients of the 
“tumor” cohort and 58 patients of the “no tumor” cohort. No significant differences were 
detected for both CMV- (Figure 3A) and EBV-specific (Figure 3B) T-cell responses by 
comparing the two patient cohorts and each cohort with controls. The levels of T-cells 
responses against HPV before and at the time of the diagnosis of cancer in the “tumor” cohort 
were significantly lower if compared with those detected in healthy donors. Significantly 
lower levels of HPV-specific T-cells responses were also observed between both baseline and 
follow up in the “no tumor” cohort and in healthy donors (Figure 4). Table 3 summarizes the 
mean and median values obtained in both cohort of patients at baseline and follow up.  
 
 
Table 3. T-cell responses against virus mix derived-peptides in SOTs 
   “Tumor” cohort  “No Tumor” cohort  Donors 
   Baseline  Diagnosis  Baseline  Follow up   
CMV Mean  753  548  558  906  269 
SD  886  331  788  1177  289 
Median  410  459  337  487  95 
EBV Mean  217  271  212   307  134 
SD  350  417  322  425  120 
Median  84  58  101  143  80 
HPV Mean  18  121  81  171  235 
SD  36  239  268  495  173 
Median  7  12  10  21  280 
TOT pts   15  58  5 
 
 
 B Tc vs 
D Tc 
B Tc vs B 
NTc 
B Tc vs F 
NTc 
B Tc vs d D Tc vs B 
NTc 
D Tc vs F 
NTc 
D Tc vs d B NTc vs 
F NTc 
B NTc vs 
d 
F NTc vs 
d 
p-values 
CMV 0.834 0.472 0.849 0.222 0.267 0.741 0.190 0.112 0.407 0.159 
p-values 
EBV 0.787 0.857 0.322 0.897 0.810 0.298 0.928 0.142 0.772 0.358 
P-values 
HPV 0.280 0.575 0.012 0.002* 0.575 0.303 0.037* 0.030* 0.005* 0.021* 





Figure 3. Spontaneous T cell responses against CMV and EBV mix peptides. All tests were performed using PBMCs 
from patients at different time point. The number (enumerated as SFC, spot forming cells) of TAA-specific T cells responses 




          Figure 4. Spontaneous T cell responses against HPV mix peptides. All tests were  performed using  PBMCs from  
          patients at different time point. The number (enumerated as SFC, spot forming cells) of  TAA-specific T cells 







3.3 Phenotypic and Functional analyses  
 
 
3.3.1 Immunophenotypic characterization of T-cells from SOT patients. 
Globally, peripheral T lymphocytes from 27 patients were investigated for the main markers 
of senescence, exhaustion and activation (Table 4). In parallel, samples from the same 
patients were analyzed for the activation status of T-cells and DCs through multispectral 
imaging flow cytometry. Patients were stratified for the onset (n=6 patients) or absence (n=21 
patients) of tumor during surveillance. Patients’ whole blood was labeled with CD3-FITC, 
CD4-APC-H7, HLA-DR-PerPC-Cy5.5, CD38-PE-Cy7, Tim-3-APC antibodies and with 
CD3-PerPC-Cy5.5, CD4-APC, CD8-APC-Cy7, CD28- PE-Cy7, CD57- FITC, PD-1-PE 
antibodies.  
13 samples from healthy donors were stained for the same antibodies. The control cohort of 
healthy donors had an average age of 55 years. Table 4 summarizes the average numbers of 




 compartments, respectively, 
at a single time point. The percentages of the investigated subpopulations were stable in the 
serial samples investigated for each patient. No significant differences were observed between 
the two cohorts for any of the subpopulations considered and also compared to healthy 
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 T-cells of SOT patients 
 
 
 “Tumor”cohort “No tumor” cohort Donors 
 Mean SD Mean SD Mean SD 
% tot        
CD3+CD4+  41.93% 8.78 46.12% 10.83 44.58% 6.01 
CD3+CD8+ 27.13% 10.89 22.15% 9.41 19.57% 6.15 














 20.70% 19.05 28.28% 17.79 21.12% 15.84 




















  3.58% 4.08 2.38% 2.05 3.47% 3.57 














 4.75% 3.43 3.27% 2.64 NA NA 
 







3.3.2 Evaluation of immune cells activation status through multispectral imaging flow 
cytometry  
The activation status of the immune cells involved in antigen-presentation (DCs) and effector 
functions (T-cells) was investigated by analyzing a functional marker in an assay based on 
multispectral imaging flow cytometry. Multispectral imaging flow cytometry allows a precise 
enumeration of cells carrying a nuclear translocation of the NF-κB p65 protein, as a 
functional marker of NF-κB activation. A recent study carried out in our laboratory in 
oligometastatic breast cancer patients treated with stereotactic body radiotherapy, the number 
of circulating NK cells showing NF-kB nuclear translocation correlated with an increase in 
perforin production and NK cell-mediated cytotoxicity (147). We have also previously 
demonstrated that the number of circulating NK cells showing NF-kB nuclear translocation 
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correlated with the induction of a pathologic complete responses in HER2
+
 breast cancer 
patients treated with a neo-adjuvant chemio-immunotherapy schedule (148) 
Patients’ PBMCs were stained for anti-NF-κB/p65-PE and DRAQ5 for nuclear imaging. Cells 
were run on the ImageStreamX cytometer using the INSPIRE software and imaged. Cells that 
were in focus were positive for both DRAQ5 and NF-kB/p65 and images were analyzed using 
the IDEAS software. The extent of internalization was calculated with an algorithm of the 
IDEAS software that measures the similarity score between DRAQ5 and NF-kB staining. A 
similarity score is determined for every cell based on a pixel by pixel correlation of the 
nuclear image to the NF-kB image (Figure 5). The threshold of similarity score to consider 
translocated NF-kB was defined using as negative and positive control ML-1 cell line 






Figure 5. NF-kB nuclear translocation. A) Representative figure of NF-kB translocation in INF-γ DCs. The positivity of 
acquired events was established through correlation between similarity score of DRAQ5 and NF-kB staining. For dendritic 
cells the score was set at 0.5. B) Representative figure of NF-kB translocation in CD4+ T cells. The positivity of acquired 
events was established through correlation between similarity score of DRAQ5 and NF-kB staining. For T cells the score was 







       Figure 6. ML-1 cell line untreated or treated with TNF-α was used as a negative and positive control, respectively,  





3.3.3 NF-kB nuclear translocation in circulating T lymphocytes  
To evaluate the activation status of patient T lymphocytes, PBMCs were labeled with CD4-
FITC and CD8-PC7 antibodies. After permeabilization, T-cells were labeled with NF-kB/p65-
PE antibody and DRAQ5. Cells were run on ImageStreamX cytometer using 488nm and 
785nm laser excitation and 30000 events were acquired for each sample. Patients were 
stratified for the onset (n=6 patients) or absence (n=21 patients) of tumor during surveillance. 
T cells from healthy donors (n=4) were stained with the same protocol as control. In the 
“tumor” cohort, significantly lower numbers of activated CD4
+
 T cells were observed after 
tumor onset as compared to the baseline. The numbers of activated  CD4
+
 T cells detected in 
the “tumor” cohort after tumor development were significantly lower than those observed at 
baseline in the “no tumor” cohort or in healthy donors (Figure 7A). The activation status of 
CD8
+
 T cells at diagnosis was significantly decreased if compared with the activation status 
of the same cells in healthy controls. On the contrary, the group of “no tumor” patients 
retained a nearly normal level of CD8
+
 T-cell activation at both baseline and follow-up 




 T cells 




Table 5. “Tumor” patients  
 CD4+ T cells 
baseline 
CD4+ T cells 
diagnosis 
Donors 
CD4+ T cells 
CD8+ T cells 
baseline 
CD8+ T cells 
diagnosis 
Donors 
CD8+ T cells 
% cells gated 46.59% 50.69% 40.2% 19.30% 12.61% 21.65 
Mean NF-kB 38.90% 21.68% 44.65% 35.80% 22.81% 42.96% 
SD 11.64 13.56 2.73 12.42 16.45 2.30 
Median NF-kB 41.485 20.835 44.64 39.009 26.4 42.95 
 
 
Table 5. “No tumor” patients 
 CD4
+ T cells 
baseline 
CD4+ T cells 
follow-up 
Donors 
CD4+ T cells 
CD8+ T cells 
baseline 




% cells gated 51.40% 76.46% 40.2% 20.05% 17.23% 21.65 
Mean NF-kB 38.16% 37.17% 44.65% 38.45% 38.10% 42.96% 
SD 14.10 14.14 2.73 14.10 15.04 2.30 





 p values CD4
+ 




Baseline Tc vs Diagnosis Tc 0.040* 0.156 
 
Baseline Tc vs Baseline NTc 0.899 0.665 
 
Baseline Tc vs Follow up NTc 0.767 0.711 
 
Baseline Tc vs Donors 0.294 0.224 
 
Diagnosis Tc vs Baseline NTc 0.030* 0.071 
 
Diagnosis Tc vs Follow up NTc 0.039* 0.077 
 
Diagnosis Tc vs Donors 0.008* 0.029* 
 
Baseline NTc vs Follow up NTc 0.822 0.938 
 
Baseline NTc vs Donors 0.074 0.192 
 
Follow up NTc vs Donors 0.042* 0.184 






Figure 7. Effects of IS treatment on NF-kB nuclear translocation in T cells. 2x106 PBMCs of each sample were strained 
with CD4-FICT, CD8-PEPC7, NF-kB-PE and DRAQ5 antibodies. Cells were run on ImageStreamX cytometer using 488nm 
and 785nm laser excitation and  were collected 30000 events for each samples. A) Graphs represent the % of nuclear NF-kB 
nuclear translocation in CD4+ T cells of each group of samples, stratified for tumor and no tumor event, both at baseline and 
follow up (*p < 0.05, t Student test). NF-kB nuclear translocation was evaluated by multispectral imaging flow cytometry 
through the Similarity Score (SS) algorithm. NF-kB/DRAQ5 SS indicates the percentage of T cells with NF-kB translocated 
into the nucleus. B) Graphs represent the % of nuclear NF-kB nuclear translocation in CD8+ T cells of each group of samples, 
stratified for tumor and no tumor event, both at baseline and follow up (*p < 0.05, t Student test). NF-kB nuclear 
translocation was evaluated by multispectral imaging flow cytometry through the Similarity Score (SS) algorithm. NF-




3.3.4 NF-kB nuclear translocation in monocyte-derived DCs 
Monocytes from patients’ PBMCs were cultured in duplicate for 1 week with GM-CSF and 
IL-4 for differentiation in iDCs. At day 6 of culture, LPS + IFN-γ were added O/N as 
maturation stimulus, and mDCs were harvested at day 7 of culture. Subsequently, DCs were 
labeled with CD3-FITC and CD14-ECD antibodies to exclude contaminating lymphocytes 
and myeloid cells from the analysis.  After permeabilization, DCs were labeled with the NF-
kB/p65-PE antibody and DRAQ5. Cells were run on ImageStreamX cytometer using 488nm 
and 785nm laser excitation and 20000 events were collected for each sample. Patients were 
stratified for the onset (n=6 patients) or absence of cancer (n=20 patients) occurred during 
surveillance. DCs from healthy donors (n=4) were cultured and stained with the same 
protocol. The number of INF-γ DCs with activated nuclear NF-kB was significantly lower at 
diagnosis in the “tumor” cohort. Activation status of INF-γ DCs at diagnosis was also 
significantly lower if compared with activation status at both baseline and follow up in the 
“no tumor” cohort. Activation status of IFN-γ DCs of both cohorts at baseline and follow up 




8). Table 6 summarizes the average and median numbers of IFN-γ DCs showing NF-kB 
nuclear translocation at baseline and at follow up in both cohorts. 
 
 
Table 6. Tumor patients 
 IFN-γDCs baseline IFN-γDCs Diagnosis IFN-γDCs Donors 
Mean NF-kB 16.53% 13.19% 29.25% 
SD 5.77 4.94 2.86 
Median NF-kB 17.34 13.9 29.25 
 
 
Table 6. No tumor patients 
 IFN-γDCs baseline IFN-γDCs follow-up IFN-γDCs Donors 
Mean NF-kB 20.79% 20.72% 29.25% 
SD 12.82 13.51 2.86 





 p values IFN-γ DCs 
Baseline Tc vs Diagnosis Tc 0.308 
Baseline Tc vs Baseline NTc 0.265 
Baseline Tc vs Follow up NTc 0.287 
Baseline Tc vs Donors 0.002* 
Diagnosis Tc vs Baseline NTc 0.041* 
Diagnosis Tc vs Follow up NTc 0.050* 
Diagnosis Tc vs Donors 0.000* 
Baseline NTc vs Follow up NTc 0.987 
Baseline NTc vs Donors 0.019* 
Follow up NTc vs Donors 0.022* 





Figure 8. Effects of IS treatment on NF-kB nuclear translocation in  INF-γ DCs. 1x106 DCs of each  sample 
were strained with CD4NF-kB-PE and DRAQ5 antibodies. Cells were run on ImageStreamX  cytometer using 
488nm and 785nm laser excitation and  were collected 20000 events for each samples. NF-kB nuclear translocation 
was  evaluated by multispectral imaging flow cytometry through the Similarity Score (SS) algorithm. NF-







3.3.5 Iatrogenic immunosuppression impairs maturation of DCs generated from healthy 
donors  
To more directly investigate the functional impact of immunosuppressive drugs on DCs, we 
have also characterized by flow cytometry the phenotypic profile of DCs generated from 
healthy donors and treated with Tacrolimus or Everolimus in vitro. DCs were isolated and 
matured from purified CD14
+
 cells obtained from 4 healthy donors and cultured with the 
same protocol adopted for patient-derived DCs. DCs derived from healthy donors were 
treated with Tacrolimus (TAC) or Everolimus (EVR) at different concentrations (Figure 9). 
mDCs were labeled for the main lineage markers, HLA-DR-PeCy7 and CD11c-PerCP-Cy5.5 
antibodies, and for the main maturation markers, CD86-BV421 and CD83-FITC antibodies. 
The results obtained showed that immunosuppressive treatment with CNI or mTORi at 
different concentrations inhibited iDCs maturation ability. The expression of HLA-DR and 
CD11c in mDCs from healthy donors treated with CIN and mTORi was significantly lower if 
compared to untreated mDCs (NT). Interestingly, the significant downregulation of CD11c 
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was observed at both concentrations of EVR. Both concentrations of EVR significantly down-
regulated CD86 expression as well as did the highest concentration of TAC. For CD83, 
however, we did not observe significant changes in cells treted with TAC, although a trend to 
a lower expression of these markers was detected. On the contrary, both concentrations of 






Figure 9. Flow cytometry evaluation of lineage and maturation markers. Immunophenotyping of DCs from healthy 
donors was performed to through the analysis of the expression of the main line and maturation markers. The differentiation 
of IFN-γ DCs from healthy donors was investigate after a week of culture in the presence of two different concentration of 









4. Discussion  
Although pharmacologic immunosuppression is essential to prevent allograft rejection 
in SOTs, it may be variably associated with an increased risk of tumor development and 
reduced control of viral infections by the immune system. Despite the availability of new 
immunosuppressive drugs, such as mTORi, the possibility of developing a cancer 10 years 
after transplantation remains high in these patients. Various concomitant factors play a 
fundamental role in this scenario, such as the duration of the immunosuppressive regimen, the 
age of transplantation, physiological aging and especially the persistence of opportunistic 
infections by oncogenic virus. 
Available data clearly indicate that SOT patients have a 2-5-fold higher risk to develop 
a De Novo neoplasm compared to the general population (4). In particular, the increased risk 
correlates with the duration of iatrogenic immunosuppression, which may markedly reduce 
the efficacy of host immune immune-surveillance. This may result in uncontrolled 
proliferation of tumor cells and sustained reactivation/replication of oncogenic viruses, 
particularly HPV and EBV, which are pathogenically associated with non-melanoma skin 
cancer and lymphoproliferative diseases, respectively. Non-oncogenic latent viruses may also 
play a role in tumor development in SOTs, due to their ability to inhibit T-cell functions, as in 
the case of CMV, whose infection/reactivation may result in loss of the replicative capacity of 
immune effector cells. 
The mechanisms of immune-surveillance involve different cell populations of the 
immune system, which are able to capture, process and eliminate the non-self. In particular, 
APCs are the main orchestrators of the initiation of the immune response against non-self 
viral and tumor antigens. T-cell activation is driven by the simultaneous triggering of the 
TCR/CD3 receptor and co-stimulatory molecules such as CD28 by the APCs, necessary for 
the optimal activation of T cells, resulting in migration of the NF-kB factor into the nucleus 
and massive production of IL-2 and other relevant cytokines (149,150).  
As discussed above, some immunosuppressive drugs such as CNIs may have a direct 
role in promoting neoplastic transformation, as they increase the expression of TGF-β and 
VEGF, which may promote local immunosuppression and tumor cell proliferation. In 
addition, administration of CNIs would seem to reduce the extent of NF-kB nuclear 
translocation in both T cells and DCs, respectively (106,124), consistent with decreased 
activation levels of these immune cells. Other drugs, such as mTORi, exert powerful anti-
proliferative effects, being able to inhibit neoangiogenesis and direct growth-inhibitory action 
in neoplastic cells, by blocking the mTOR pathway, a serine-threonine kinase involved in cell 
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growth, proliferation, protein synthesis and apoptosis. Despite these anti-tumor effects, 
however, mTORi may also have a negative impact on the activation and function of immune 
cells in the SOT patients (132).  
Considering that the long-term iatrogenic immunosuppression of transplanted patients 
may lead to the development of virus-unrelated and oncogenic virus-driven tumors, the 
identification of biomarkers predictive of the risk of impending tumor development 
constitutes an unmet clinical need in this setting. To address this clinically relevant issue, we 
have taken advantage of the program of clinical and laboratory surveillance of SOT patients 
recently activated at the CRO-IRCCs Aviano. The routine workup of these patients was 
implemented with a panel of phenotypic and functional immunoassays aiming to identify and 
validate, through multiparametric investigations, the potential predictive role of 
immunological biomarkers, such as CD4 and CD8 T-cell specific immune responses against 
viral and TAAs and the activation status of effector cells and DCs. 
Our results concerning the activation status of patient-derived DCs showed that, in the 
"tumor" cohort, the activation status of DCs at the time of diagnosis was significantly lower 
than that at baseline and that observed in the “no tumor cohort”. Due to the limited number of 
patients who have so far developed a tumor, it was not possible to make any informative 
stratification according to the type of treatment. With the exception of one patient who 
received a CNI+mTORi combined therapy, all patients who developed a tumor were treated 
with a CNI-based immunosuppressive regimen. Despite the limited size of our cohort, we 
observed a significant decrease in the level of NF-kB activation in IFN-γ DCs generated from 
these patients, consistently with previous findings on the inhibitory effects exerted by CNIs 
on immune cells (124,125). In the cohort of SOT patients who did not develop tumor 
(CNI=15; mTORi=2; CNI +mTORi=3), we observed that IFN-γ DCs were significantly less 
activated as compared to healthy donors, both at baseline and during follow-up. Globally, the 
activation status of IFN-γ DCs in the “tumor” cohort was lower than that observed in SOT 
patients of  the “no tumor” cohort, suggesting that DC activation could constitute a potential 
predictive marker. Nevertheless, the interpatient variability of the data observed together with 
the limited sample size of this pilot study did not allow the identification of a cut-off value of 
potential applicative relevance. These findings may also have pathogenic implications, 
suggesting that a more profound impairment in DC activation could lead to suboptimal 
generation of anti-tumor T-cell immunity, thus engancing the risk to develop a tumour in 
chronically immunosuppressed SOT recipients.  
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The analysis of NF-kB nuclear translocation gave similar results with regard to the 




 T-cells in the “tumor” 
cohort before the diagnosis of cancer, was comparable to that of tumor-free SOT patients and 
healthy donors. These findings are consistent with a retained ability of these T-cell 
subpopulations to be activated at near-physiological levels despite the treatment with 





lymphocytes at the time of diagnosis of cancer was significantly lower than that observed in 
the same patients prior to tumor onset. 
Although the number of patients analyzed in the present study is too limited to draw 
definite conclusions, our results suggest that inclusion of the analysis of the activation profile 
of T cells and DCs in a larger prospective study could validate the potential role of these 
biomarkers as predictive of the cancer onset in SOT patients.   
A larger number of patients were analyzed by ELISpot assay to monitor the number of 
IFN-γ-releasing T-cells against viral and TTA epitopes. Of note, significantly higher numbers 
of T-cells specific for hTERT and Survivin were detected at the time of diagnosis of cancer in 
the blood of SOT patients although with a certain degree of variability among patients. These 
findings indicate that, despite iatrogenic immunosuppression, SOT patients developing a 
tumor are able to mount IFN-γ T-cell responses against “universal” TAAs, such as hTERT 
and Survivin. These findings are of particular relevance in the light of the possible role of T-
cell responses specific for hTERT and Survivin as potential biomarkers of impending tumor 
development in these patients. Globally, IFN-γ T-cell responses against hTERT and Survivin 
in the “no tumor” cohort were on average lower than those of the “tumor” cohort, with the 
only exception of the specific T-cell responses detected against Survivin in the follow up of 
the “no tumor” cohort.  Notably, in these cases, Survivin-specific T-cells responses were 
significantly higher compared to healthy donors. Survivin is an inhibitor of apoptosis that 
interferes with post-mitochondrial events including activation of caspases  The detection of 
increased T-cell responses to Survivin during the follow-up in the cohort of cancer-free 
patients is intriguing and deserves further investigation to better understand its biological 
meaning and particularly whether it may help predicting the risk of cancer in this setting. 
These findings provide the rationale to prospectively analyze T-cell responses to universal 
TAAs in a large series of SOT patients to better define the potential contribution of these 
analyses to the definition of their risk of cancer. 
Considering that elevated hTERT mRNA in peripheral blood is closely related with 
clinicopathological parameters, treatment efficacy and other tumor biomarkers of cancer 
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patients, we implemented our immune profiling with the quantification of circulating hTERT 
mRNA in our SOT cohorts. The rationale for this investigation was also supported by the 
finding of increased T-cell responses specific for hTERT in SOT patients developing a tumor. 
Globally, patients of the “tumor” cohort showed significantly higher levels of circulating 
hTERT mRNA as compared to those of the “no tumor” cohort. These findings are consistent 
with available data indicating that hTERT expression is specific of the transformed phenotype 
(151–153). In fact, several studies have been demonstrated that circulating TERT mRNA is an 
independent prognostic marker in different types of tumors. Circulating TERT mRNA was 
found in plasma samples of patients with gastric cancer but was not detected in plasma 
samples of healthy volunteers (154). Plasma hTERT mRNA levels were also detected in 
patients with elevated PSA levels and associated with poor prognosis, potentially behaving as 
a factor indicative of biochemical recurrence (155). In addition, hTERT mRNA levels in 
plasma samples of patients with colorectal (146) or lung cancer were identified as possible 
promising non-invasive tumor biomarker in clinical practice (156). Our findings are 
consistent with the available data mentioned above, indicating that hTERT expression is 
specific of the transformed phenotype (151–153). Our observation that the levels of TERT 
mRNA were significantly higher even before the diagnosis of cancer in the “tumor” cohort is 
intriguing and strongly suggests the potential clinical relevance of the inclusion of circulating 
hTERT mRNA among the biomarkers to investigate in a prospective study in this setting. 
The analysis of T-cell responses against CMV and EBV antigens did not disclose any 
significant difference between the two cohorts of SOT patients and between baseline and 
follow up samples, although the numbers of antigen-specific T cells were on average higher 
than those detected in healthy controls. Infections with these viruses are highly prevalent in 
the general population, and the immunosuppressive regimen can trigger viral reactivation or 
facilitate post-transplantation infection, thus accounting for the maintaining of proficient 
memory responses to these viruses. The fact that we did not observe significantly increased 
levels of T-cell responses to EBV is consistent with the observation that, in our series, no 
patient developed a EBV-related cancer thus preventing the possibility to assess the predictive 
value of this analysis in our cohort of patients. In a recent retrospective study, 197 solid organ 
transplant recipients were examined to study the reactivity of EBV-specific lymphocytes 
using the ELISpot assay. The results obtained, combined with the EBV viremia data, we can 
see how this approach can be a tool to guide the modulation of immunosuppression in patients 
with active EBV replication, since the values of the viremia tended to be higher in the first 
year after transplantation in the group of patients with a positive positive immune response 
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specific for positive EBV (157). With regard to CMV infection in solid organ transplant 
recipients, post-transplant CMV immune monitoring can guide the duration of antiviral 
prophylaxis, identify recipients at risk of CMV disease and predict recurrent CMV 
reactivation (158). Banas B et al have demonstrated the validity of the use of the ELISpot 
assay in the monitoring of CMV infection, as the specific response to CMV has decreased as 
a result of immunosuppressive treatment and is increased in patients with graftrejection, 
indicating the ability of the ELISpot test to monitor the status immunosuppressive treatment 
of patients (159).  
Intriguingly, the levels of HPV-specific T-cell responses observed in both patient 
cohorts were significantly lower both at baseline and at follow up as compared to those of 
healthy donors. These findings markedly contrast with the almost preserved level of T-cell 
responses against the herpesviruses EBV and CMV. This difference could be due to the fact 
that herpesvirues may undergo spontaneous reactivations over time, thereby maintaining the 
pool of memory T cells specific for these viruses. The iatrogenic immunosuppression 
characterizing SOT patients may also promote EBV and CMV reactivation. Although our 
knowledge of memory immune responses specific for HPV is limited, this virus has a 
completely different lifecycle and is probably less prone to reactivation as compared to 
herpesviruses.  It is worth considering however, that 60% of patients of the “tumor” cohort 
have developed a non-melanoma skin cancer, which are often associated with HPV-β 5 and 7. 
The HPV peptide mix used in our ELISpot assays is composed primarily of peptides 
associated with the high-risk HPV strains 16 and 18, associated with tumors of genital tract, 
and this may at least in part explain the low responses detected, although the possibility of a 
cross-reactivity can not be ruled out. Further studies using a mix of peptides belonging to the 
-HPV 5 and 8 strains are also required to assess the potential predictive value of T-cell 
responses against these beta HPV. However, HPV can be expected to play a role in the 
initiation processes of oncogenesis, acting as a co-carcinogen with some drugs, such as CNI 
(71, 153). Notably, all patients of this cohort were treated with a CNI-based 
immunosuppressive regimen. These findings are consistent with the hypothesis that the lower 
levels of HPV-specific T-cell responses coupled with the oncogenic effects of CNI treatment 
may act synergistically to increase the risk of non-melanoma skin cancer in SOT patients.  
Our results, even if preliminary and on a small cohort, show that, in SOT patients, it 
would be clinically relevant to implement a specific program of oncological (immune) 
monitoring, which takes into account the different variables present in such complex patients. 
Monitoring programs should also be integrated with various investigative strategies that can 
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identify and prospectively validate markers predictive of de novo tumors, to be combined with 
already established approaches that help identify high-risk patients. To the best of our 
knowledge, this is the first comprehensive immunomonitoring study in a prospective cohort 
of SOT patients aimed at identifying such biomarkers. The results obtained in this pilot series, 
although not conclusive, are consistent with the hypothesis that the identification of 
phenotypic and/or functional changes in immune cells, coupled with the detection of early 
tumor markers such as TERT, may indeed provide a more precise estimate of the risk of 
cancer in SOT patients. In perspective, we plan to implement our work by performing 
phenptypic and functional analysis in T-cells and DCs and monitoring the levels of  
spontaneous T-cells responses in a larger prospective series, which  may allow patient 
stratification according to for the type of immunosuppressive therapy administered. We also 
plan to evaluate the cytokine and chemokine secretion profile in the  supernatants of all 
cultures performed in this study, in order to provide a more complete immune profile of SOT 
patients and identify correlations of potential clinical relevance. In addition, given that CNIs 
but also of mTORi, may  modulate the ability of the NF-kB transcription factor to migrate 
into the nucleus, it is likely that these same drugs may also interfere with the intracellular 
trafficking of other transcription factors or with the activation of other signal transduction 
pathways. In particular, though a trascriptome analysis and differential gene expressions 
profiling, we plan to e indentify a predictive DC immune signature that we hypothesize could 
be modulated by different immunosuppressive regimens The interesting preliminary data that 
will be obtained on DCs derived from healthy donors treated with different drugs, can then be 
validated and confirmed on material derived from patients, always with the prospect of 
identifying an immune signature that can, together with the other markers, provide a complete 
profile predictive of the onset of de novo tumors in these patients. 
In conclusion, the results of the present study provide a strong rationale to design and 
activate a prospective study in a larger cohort of SOT patientsto validate the encouraging 
results obtained in a pilot cohort with the final goal to identify reliable biomarkers able to 









5. Material and Methods 
 
5.1 Immunosurveillance protocol  
The immunosurveillance protocol for SOT recipients activated at the Centro di Riferimento 
Oncologico (CRO) in Aviano (PN) proposes a surveillance program focused on the most 
frequent and diagnosable de novo tumors with standardized screening (skin, lung, kidney, 
rectum, cervix and pharynx carcinomas) with integrated immune-virological and clinical 
follow-up. The study includes a sub-project of translational research to identify candidate 
biomarkers predictive of the development of de novo tumors in OTRs. 
Patients are stratified according to the type of transplant (kidney, heart, liver) and, within each 
category, the high and low risk of tumor development during surveillance is determined. 
 
The group of high risk (HR) includes transplant recipients with at least one of these risk 
factors:  
 Duration of immunosuppression ≥ 10 years 
 Age of transplant ≥ 50  
 Multiple non-synchronous transplants 
 Abuse of smoking, tobacco, alcohol. 
 HIV infection 
 
The group of low risk (LR) includes transplant recipients with at least one of these risk 
factors:  
 
 Duration of immunosuppression < 10 years 
 Age of transplant < 50  
 Single or multiple synchronous transplants 
 Absence of smoking, tobacco, alcohol. 
 Absence of HIV infection 
 
Eligibility criteria:  
a) Time from transplantation ≥ 1 year 
b) Age ≥ 18 
c) Performance status ECOG: 0-2 
d) Life expectancy ≥ 6 months  
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e) Compliance of regular follow up 
f) Informed consent 
 
Exclusion criteria: 
a) Pre-transplanted tumors with exclusion of non-melanoma skin cancer, Tis cervix and 
hepatocellular carcinoma in liver transplant recipients. 
b) Post-transplant and pre-enrollment tumors of active disease or complete remission < 3 
years, with exclusion of non-melanoma skin cancers and Tis cervix. 
c) severe co-morbidities at enrollment or in the previous year: heart failure, myocardial 
infarction, stroke, severe hepatic and / or renal failure, tuberculosis, psychiatric 
pathology. 
d) acute rejection at the time of enrollment 
e) Pregnancy 
 
Removal criteria from the study:  
a) Development of tumors requiring chemo and / or radiotherapy 
b) Development of tumors treated with root surgery, cutaneous carcinomas are excised 
c) Myocardial infarction, heart failure, stroke, infections require long-term therapy (eg 
tuberculosis), severe hepatic and / or renal insufficiency, psychiatric pathology. 
d) Retreat of informed consent 
e) Serious non-compliance with the surveillance program. 
 
HR patients have an intensive surveillance focused on more frequent de novo tumors and 
diagnosed with standardized screening, such as carcinoma of the skin, lung, kidney, HCC, 
colorectal carcinomas, cervix, head-neck and esophagus. LR patients follow the general 
population guidelines (161) Breast and prostate cancer screening follows the general 
population guidelines in both groups. 
 
General clinical evaluation includes “surveillance oncology visit” and laboratory tests of 
organ functionality. The general assessment is performed every 6 months for HR patients and 
annually for LR patients. Standard laboratory tests are performed regularly every 3 months in 
the patient's transplant centers. 
 
Immuno-virological screening comprise: 
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 Serology for HBV, HCV and HHV8. 
 Viremia for EBV, HHV8, CMV e BKV in patients with documented viruria 
 Basic immunological evaluation, focused on the quantitative evaluation of lymphocyte 
subpopulations: B lymphocytes (CD19), T helper (CD4), cytotoxic T (CD8) and 
Natural Killer (CD16) 
 Immuno-phenotype of senescent and activate CD4 and CD8 T cells. 
 Maturation and differentiation status of DCs   
 Antigen-specific functional investigations: T cell responses against TAAs (tumor 
associated-antigens) and viral antigens (EBV, CMV, HPV) through ELIspot IFN-
γ assays.  
 Activation status and nuclear NF-kB translocation on T cells and DCs through 
multispectral imaging flow cytometry (ImageStreamX). 
 
5.2 Patients, treatment and healthy donors 
The enrollment protocol to the program of oncologic immune-surveillance of De Novo tumor 
in SOT patients was approved recently at Centro di Riferimento Oncologico (CRO) in 
Aviano. Our laboratory enrolled 111 patients who received kidney (87), heart (10), liver (7) 
and double transplant (7, of which: kidney+kidney, heart+kidney, kidney+pancreas). Patients 
who had organ rejection or return to dialysis were excluded of surveillance. We stratified our 
patients according to the main currently used immunosuppressive drugs: 2 patients treated 
with AZA, 88 patients treated with CNI, 10 patients treated with mTORi and 11 patients 
treated with both drugs.. Healthy donors used were collected in our lab from 2012.  
  
5.3 Sample collection  
Blood samples were collected from all patients at the moment of the first visit and during the 
follow-up. Fresh heparinized peripheral blood was centrifuged at 800 rpm for 10 minutes 
within 4 hours of withdrawal. The plasma fraction was further centrifuged at 2100 rpm for 15 
minutes, aliquoted in two vials and frozen at -80°C. Peripheral blood mononuclear cells 
(PBMCs) were isolated from patients by Ficoll-Hypaque gradient. Cells were washed once in 
PBS and counted by ADAM Cell Counter (DigitalBio). PBMCs were resuspended in 1ml of 
FCS containing 10% DMSO and were stored viably to perform functional  analysis and 





5.4 Antibodies and reagents 
CD3-FITC (mouse IgG1, clone UCHT1) was purchased from Dako. CD4-APC (mouse IgG1, 
clone RPA-T4), CD4-APC-H7 (mouse IgG1, clone RPA-T4), CD8-PE (Mouse BALB/c 
IgG1, clone SK1), CD8-APC-Cy7 (mouse IgG1, clone SK1), CD28- PerCP-Cy7 (Mouse C3H 
x BALB/c IgG1, clone CD28.2), CD38-PE-Cy7 (mouse IgG1, CLONE HB7), CD57-FITC 
(mouse IgM, clone HNK-1), PD-1-PE (mouse IgG1, eh12.1), CD8-PE-Cy7 (mouse IgG1, 
clone RPA-T), CD11c-PerCP-Cy5.5 (BALB/c mice IgG1, clone X63), CD83-FITC (mouse 
IgG1, clone HB15e), CD86-BV421 (mouse BALB/c IgG1, clone 2331 (FUN-1)), HLA-DR-
PE-Cy7 (mouse IgG2a, clone G46-6) αCD3 and αCD28 were purchased from BD Biosciences 
(Becton Dickinson). CD3- FITC (mouse IgG1,clone UCHT1), CD4-FITC (mouse IgG1, clone 
13B8.2) and CD14-ECD (mouse IgG2a, clone RMO52) were purchased from BC (Beckman 
Coulter). NF-kB-PE (rabbit IgG, clone D14E12) was purchased from Cell Signaling 
Technology. HLA-DR- PerCP-Cy5.5 (mouse IgG2a, clone L243) was purchased by 
BioLegend. Human TIM-3-APC (Rat IgG2a, clone 344823) was purchased by R&D System. 
CD14 human Microbeads and LS columns were purchased from MiltenyiBiotec. Lysing 
solution was purchased from BD Biosciences (Becton Dickinson). ProMix CMV, EBV, HPV, 
Survivin and hTERT peptides pools were purchased from ProImmune. LIVE/DEAD Fixable 
Aqua Dead Cell Stain Kit was purchased from ThermoFisher Scientific. Vital nuclear dye 
DRAQ5 (DR50200) was purchased from Alexis Biochemicals. GM-CSF, IL-4 and IFN-γ 
were purchased from Promokine supplied by Bio-Connect.  
 
5.5 Patients-derived dendritic cell generation  
Briefly, PBMCs were thawed, washed once in PBS and placed in 2 well for each patient in 24 
well plate in 2 ml RMPI medium serum free for 2 hour. Subsequently, lymphocytes in 
suspension were collected and washed in PBS. Adherent monocytes were cultured for 1 week 
in cellGRO medium with GM-CSF 50ng/ml and IL-4 25ng/ml. On days 2 and 5 of culture, 
fresh medium containing the same cytokine amount as on day 0 was added. At the 6th day 
were added O/N maturative stimulus, 1.5 ug/ml LPS + 20 ng/ml IFN-γ, and dendritic cells 
were harvested on day 7 of culture.  
 
5.6 Multispectral imaging flow cytometry analyses 
5.6.1 Lymphocytes staining 
T cells staining was performed using CD4-FITC  and CD8-PE-Cy7 antibodies for 2x10^6 
cells for 20 minutes in ice. T cells were washed twice with 5ml of PBS-BSA 5%, fixed in 1ml 
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of complete RPMI containing PFA 2% and permeabilized with 600ul methanol 90% for 10 
minutes in ice. Cells were washed once with PBS-BSA 5% and incubated with NF-kB/p65-
PE antibody for 45 minutes in ice. After incubation cells were washed  once with PBS-BSA 
5% and resuspended in 70ul of PBS containing PFA 1% and DRAQ5. Cells were run on 
ImageStreamX cytometer using the INSPIRE software and images were analyzed using the 
IDEAS software (Amnis). Cells were excited with a 488-nm laser (50 mW intensity) and 785-
nm laser (0.50 mW intensity). Brightfield, side scatter, and fluorescent cell images were 
acquired at ×40 magnification. For each samples 30000 cells were collected . The extent of 
internalization was calculated with an algorithm of the IDEAS software that measures the 
similarity score between DRAQ5 and NF-kB staining. A Similarity score is determined for 
every cell based on a pixel by pixel correlation of the nuclear image to the NF-kB image. The 
threshold of similarity score to consider translocated NF-kB was defined using as n egative 
and positive control ML-1 cell line untreated or treated with TNF-α, respectively.  
 
5.6.2 Dendritic cells staining 
After stimulus incubation O/N immature (no stimulus) and mature dendritic cells were 
collected, washed in PBS, fixed in complete RPMI containing PFA 2% and permeabilized 
with methanol 90% for 10 minutes. After that DCs were washed and incubated with NF-
kB/p65-PE antibody (for 45 minutes in ice. Cells were washed and resuspended in 70ul of 
PBS containing PFA 1% and DRAQ5 Cells were run on ImageStreamX cytometer using the 
INSPIRE software and images were analyzed using the IDEAS software (Amnis). Cells were 
excited with a 488-nm laser (50 mW intensity) and 785-nm laser (0.50 mW intensity). 
Brightfield, side scatter, and fluorescent cell images were acquired at ×40 magnification. 
Were collected 20000 events for each samples. The extent of internalization was calculated 
with an algorithm of the IDEAS software that measures the similarity score as described in 
the previous paragraph. 
 
5.7 ELISpot assay 
Spontaneous T cell responses were quantified by ELISpot-IFN-γ assay commercial kit 
(Cellular Technology Limited (CTL), Human IFN gamma IMMUNOSPOT; OH, USA) . 
Ninety-six-well plates were pre-coated with anti-human interferon (IFN)-γ Capture antibody 
(2 μg/ml) O/N at 4°C. Next day PBMCs were tawed and washed once in RPMI 1640 serum 
free, counted and resuspended in CTL-test Medium in a concentration of 10.5x10^6 for each 
samples. Unspecif stimimuli (0.5 mg/ml αCD3/αCD28) and peptide mix (0.2 ng/ml of each 
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peptide mix) were resuspended in CTL-test Medium, placed (in triplicate) and incubated for 
10-20 minutes. Patients’s PBMCs were tawhed, washed and were placed (500,000 cell/well)  
in co-culture with viral (CMV, EBV and HPV) and tumor associated antigens (TAAs) 
(Survivin and hTERT) and incubated O/N. At day 3 spots were detected with anti-human 
IFN-γ (biotin), streptavidinalkaline phosphatase, and Blue Developer Solution. Spots were 
counted and analyzed by ImmunoSpot plate scanning and analysis service (Bonn, Germany). 
 
5.8 Quantification of circulating TERT mRNA 
The expression of TERT transcripts in the plasma samples was quantified by real-time PCR. 
Primers AT1 (5′-CGGAAGAGTGTCTGGAGCAA-3′) and AT2b (5′-
CGCAGCTGCACCCTCTTCA-3′) were designed on exon 3 and 4, respectively; they bind to 
nucleotide sequences located upstream of the RT motif 1 on the TERT gene allowing 
amplification of all TERT transcripts producing an amplified product of 68 bp. The 
fluorogenic probe AT (FAM 5′-TTGCAAAGCATTGGAATCAGACAGCAC-3′ TAMRA) 
recognises the sequence located inside the product amplified by AT1/AT2b. The PCR was 
performed using an ABI prism 7900 Sequence Detection System (PE Applied Biosystems, 
Foster City, CA, USA) in 50 μl of mixture containing 25 μl 2X TaqMan Universal (PE 
Applied Biosystems), 100 nM of fluorogenic probe, 600 nM of primer AT1, 900 nM of primer 
AT2b and 10 μl of cDNA sample. After 2 min at 50 °C to allow the uracil N-glycosylase to act 
and a denaturation step lasting 10 min at 95 °C, 50 cycles were run, each consisting of 30 s at 
95 °C, 30 s at 60 °C and 30 s at 72 °C. Each sample was run in triplicate and the mean Ct 
values were plotted against the standard TERT reference curve, which was generated with 
serial fivefold dilutions of the TERT amplicon, as previously described. TERT values were 
estimated per ml according to the X 8 X 2 conversion factor and then expressed as TERT 
copies per ml. Ten microlitres cDNA from each sample were also amplified for the 
housekeeping hypoxantin-guanine phosphoribosyl transferase 1 (HPRT1) gene. The forward 
primer HPRT1for (5′-TCAGGCAGTATAATCCAAAGATGGT-3′) was designed between 
exons 4 and 5, and the reverse primer HPRT1rev (5′-CTTCGTGGGGTCCTTTTCAC-3′) was 
designed on exon 6, generating a cDNA amplified product of 64 bp. The fluorogenic probe 
(VIC 5′-AAGGTCGCAAGCTT-3′ MGBNFQ) recognises the sequence located within the 
products amplified by HPRT1for/HPRT1rev. PCR was performed using an ABI prism 7900 
Sequence Detection System (PE Applied Biosystems) in 50 μl of mixture containing 25 μl 2 × 
TaqMan universal master mix (PE Applied Biosystems), 200 nM of fluorogenic probe, 
900 nM of primer HPRT1for and HPRT1rev and 10 μl of cDNA sample. The thermal cycler 
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profile consisted of 2 min at 50 °C, 10 min at 95 °C and then 45 cycles were run, each 
consisting of 30 s at 95 °C, 30 s at 60 °C and 30 s at and 72 °C. Each sample was run in 
triplicate and the mean Ct values were plotted against the standard HPRT1 reference curve, 
prepared using serial dilutions of the HPRT1 amplicon, as previously described. TERT values 
were expressed as TERT copies per 10
3
 HPRT1 copies (146).  
 
5.9 Dendritic cells from healthy donors culture generation protocol 
Dendritic cells from healthy donors were isolated from PBMCs by CD14 positive separation 
according to the protocol. Briefly, PBMCs were tawed and washed once in RPMI 1640 serum 
free and once in PBS. For each 10^7 cells were added 20ul CD14 human MicroBeads and 
80ul of MACS Buffer (PBS+BSA 0.5%+ 2mM EDTA) and stained 20 min in ice. After that 
cells were washed with 30ml of MACS Buffer. After the purification with anti-CD14-coated 
micro beads, CD14
+
 monocytes were sorted with a magnetic device in LS columns and 
washed once in PBS, counted and plated 1x10^6 for condition. On days 2 and 5 of culture, 
fresh medium containing the same cytokine amount as on day 0 was added and cells were 
treated with two different concentration of drugs (NT, 50ngLml and 200ng/ml for TAC; NT, 
1ng/ml and 10ng/ml for EVR). 
 
5.10 Flow cytometry analyses 
For the immunophenotypic analyses of DCs 1x10
6
 cells were stained with the antibodies 
listed below, anti-CD11c-PerCPCy-5.5, anti-CD83-FITC, anti-CD86-BV421, anti-HLA-DR-
PECy7, AquaLive). DCs were harvested at day 7 of culture, washed once in FACS Buffer at 
1500 rpm for six minutes at +4°C and stained with 50ul antibodies for 20 min at 4°C in plate. 
After that DCs were washed twice with 150ul of FACS Buffer and resuspended in 300ul of 
FACS Buffer. Cells were run on LSR-Fortessa (Becton Dickinson) and photomultiplier 
voltages and compensation with the CompBeads Set Anti-Mouse Ig or Anti-Rat Ig, k Sets 
(BD Biosciences). Flow cytometry data were analyzed with FlowJo (Tree Star, Ashland, OR, 
USA) software. 
Patients’ whole blood, to characterized the T lymphocytes phenotype, were stained for the 
following antibodies in two different tubes: the first was labeled CD3-FITC, CD4-APC-H7, 
HLA-DR-PerPC-Cy5.5, CD38-PE-Cy7,Tim-3-APC antibodies and the second was labeled 
with CD3-PerPC-Cy5.5, CD4-APC, CD8-APC-Cy7, CD28- PE-Cy7, CD57- FITC, PD-1-PE 
antibodies. Briefly, 100ul of whole blood for each tube were labeled with the different 
combination of 6 antibodies for 30 minutes at room temperature. Subsequently, the whole 
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blood was lysed with 1.5 ml of lysis solution for 15 minutes and vortexed. The samples were 
washed once with PBS at 1200rpm for 7 minutes, to stopped the lysis.  Samples were lysed a 
second time with lysis solution for 15 minutes and washed once with PBS at 1200rpm for 7 
minutes. After that, the supernatant was discarded and the pellet resuspended in 250ul of PBS. 
Cells were run on FACScanto (Becton Dickinson) and photomultiplier voltages and 
compensation were set with unstained and stained cells. Flow cytometry data were analyzed 
with BD FACS DIVA v7.0. 
 
5.11 Statistical Analysis 
Data obtained from multiple independent experiments were expressed as median for ELISpot 
assay and functional analysis. R software was used to determine the homogeneity of data 
distributions. The Student’s t-test for two-tailed distributions and paired data was used for 
statistical analysis of nuclear NF-kB translocation data in T cells and DCs-derived patients, 
obtained by multispectral imaging flow cytometry. The Student’s t-test was also employed to 
compare immunophenotypic data regarding of DCs from healthy donors culture. The Mann–
Whitney test was employed to compare spontaneous T cells responses against viral and TAAs 
mix peptides detected by ELISpot IFN-γ assay. In all cases, statistical significance was 
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 T cells have been and are still largely regarded as the orchestrators of immune responses, being 
able to differentiate into distinct T helper cell populations based on differentiation signals, 
transcription factor expression, cytokine secretion, and specific functions. Nonetheless, a growing 
body of evidence indicates that CD4
+
 T cells can also exert a direct effector activity, which depends on 
intrinsic cytotoxic properties acquired and carried out along with the evolution of several pathogenic 
infections. The relevant role of CD4
+
 T cell lytic features in the control of such infectious conditions 
also leads to their exploitation as a new immunotherapeutic approach. This review aims at 
summarizing currently available data about functional and therapeutic relevance of cytotoxic CD4
+
 T 
cells in the context of viral infections and virus-driven tumors. 
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